Status: Recruiting
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Participants needed: 38
Trial details
Phase: Phase 2Age: 1-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Apr 8, 2026Locations: 10
Eligibility criteria
Age: Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enr... [+27]
Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entere... [+16]